CONFERENCES

      International Congress on In Vitro Toxicology

      This is an annual conference that focuses on the use of in vitro methods for toxicity testing, with topics ranging from new assays to regulatory issues. The conference is aimed at toxicologists, researchers, and other professionals involved in the development and use of in vitro methods for toxicity testing, and provides a forum for sharing knowledge and collaborating on new approaches to reducing animal testing.

      ESTIV Congress 2024

      Date

      Jun 03, 2024 - Jun 06, 2024

      Location

      Prague, Czech Republic

      The 22nd International Congress of the European Society of Toxicology In Vitro (ESTIV 2024) is centered around the pivotal theme, ‘The Application of NAMs in Drug Discovery and Drug and Chemical Safety Assessment,’ and provides a comprehensive platform for showcasing and discussing the latest advancements and research in the field.

      The extensive scientific program features over 18 scientific sessions, complemented by dedicated lunch sessions, industry-sponsored sessions, and insightful workshops. These sessions are meticulously designed to cater to a wide spectrum of interests and specializations within the realm of in vitro toxicology.

      International Congress on In Vitro Toxicology 2018

      Date

      Oct 15, 2018 - Oct 18, 2018

      Location

      Berlin, Germany

      The Congress is hosted this year by The European Society of Toxicology In Vitro (ESTIV) to promote the development of in vitro and in silico approaches.

      See related posters

      IVTIP Spring 2011

      Date

      Apr 26, 2011 - Apr 28, 2011

      Location

      Monte Carlo, Monaco

      Organised in conjunction with the European Society with Toxicology In Vitro (ESTIV) and the Center for Alternatives to Animal Testing (CAAT), this event includes a study by PMI scientists to demonstrate whether exposure of human lung tissue to whole smoke in vitro can induce similar effects as observed in rodent inhalation studies. 

      See related posters

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.